Endothelin-1 overexpression restores diastolic function in eNOS knockout mice

Journal of Hypertension

Volumn 29, Issue 5, 2011, Pages 961-970

  Vignon Zellweger, Nicolas ^a   Relle, Katharina ^a,b   Kienlen, Elodie ^c   Alter, Markus ^a,b   Seider, Patrick ^a   Sharkovska, Juliya ^a,b   Heiden, Susi ^a   Kalk, Philipp ^a   Schwab, Karima ^a   Albrecht Küpper, Barbara ^c   Theuring, Franz ^a   Stasch, Johannes Peter ^c,d   Hocher, Berthold ^a,b  

^a DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

^b UNIVERSITY OF POTSDAM   (Germany)

^c Cardiology Research   (Germany)

^d MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

cardiovascular diseases; endothelin; nitric oxide

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; COFILIN 1; COFILIN 2; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENDOTHELIN 1; ENDOTHELIN RECEPTOR; GLUTATHIONE TRANSFERASE M2; HEAT SHOCK PROTEIN; HEAT SHOCK PROTEIN BETA 7; INDUCIBLE NITRIC OXIDE SYNTHASE; MESSENGER RNA; METHYLCROTONOYL COENZYME A CARBOXYLASE; METHYLCROTONOYL COENZYME A CARBOXYLASE ALPHA SUBUNIT; PEROXIREDOXIN 6; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE; BODY WEIGHT; CONTROLLED STUDY; DIASTOLE; DIASTOLIC BLOOD PRESSURE; DIASTOLIC DYSFUNCTION; ELECTROSPRAY MASS SPECTROMETRY; FATTY ACID OXIDATION; FEMALE; GLYCOLYSIS; HEART CATHETERIZATION; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE RELAXATION; HEART WEIGHT; HISTOLOGY; HYPERTENSION; MALE; MASS SPECTROMETRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS; SARCOMERE; TRANSGENIC MOUSE; TWO DIMENSIONAL GEL ELECTROPHORESIS; WILD TYPE;

EID: 79954778173     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e3283450770     Document Type: Article

References (58)

1. Slowinski T, Kalk P, Christian M, Schmager F, Relle K, Godes M, et al. Celltype specific interaction of endothelin and the nitric oxide system: pattern of prepro-ET-1 expression in kidneys of L-NAME treated prepro-ET-1 promoter-lacZ-transgenic mice. J Physiol 2007; 581 (Pt 3):1173-1181. (Pubitemid 46887986)
2. Rossi GP, Seccia TM, Nussdorfer GG. Reciprocal regulation of endothelin-.1. and nitric oxide: relevance in the physiology and pathology of the cardiovascular system. Int Rev Cytol 2001; 209:241-272. (Pubitemid 32911032)
3. Russell FD, Molenaar P. The human heart endothelin system: ET-1 synthesis, storage, release and effect. Trends Pharmacol Sci 2000; 21:353-359. (Pubitemid 30649671)
4. Tsukahara H, Ende H, Magazine HI, Bahou WF, Goligorsky MS. Molecular and functional characterization of the nonisopeptide-selective ETB receptor in endothelial cells. Receptor coupling to nitric oxide synthase. J Biol Chem 1994; 269:21778-21785.
5. Ohkita M, Takaoka M, Sugii M, Shiota Y, Nojiri R, Matsumura Y. The role of nuclear factor-kappa B in the regulation of endothelin-1 production by nitric oxide. Eur J Pharmacol 2003; 472:159-164. (Pubitemid 37271911)
6. Cheng TH, Shih NL, Chen SY, Lin JW, Chen YL, Chen CH, et al. Nitric oxide inhibits endothelin-1-induced cardiomyocyte hypertrophy through cGMPmediated suppression of extracellular-signal regulated kinase phosphorylation. Mol Pharmacol 2005; 68:1183-1192.
7. Ziolo MT, Kohr MJ, Wang H. Nitric oxide signaling and the regulation of myocardial function. J Mol Cell Cardiol 2008; 45:625-632.
8. Tschudi MR, Mesaros S, Luscher TF, Malinski T. Direct in situ measurement of nitric oxide in mesenteric resistance arteries. Increased decomposition by superoxide in hypertension. Hypertension 1996; 27:32-35. (Pubitemid 26017677)
9. Vasquez-Vivar J, Kalyanaraman B, Martasek P, Hogg N, Masters BS, KarouiH, et al. Superoxide generation by endothelial nitric oxide synthase: the influence of cofactors. Proc Natl Acad Sci USA 1998; 95:9220-9225. (Pubitemid 28506212)
10. DeGiusti V, Correa MV, Villa-Abrille MC, Beltrano C, Yeves AM, de Cingolani GE, et al. The positive inotropic effect of endothelin-1 is mediated by mitochondrial reactive oxygen species. Life Sci 2008; 83:264-271.
11. Taylor BS, de Vera ME, Ganster RW, Wang Q, Shapiro RA, Morris SM Jr, et al. Multiple NF-kappaB enhancer elements regulate cytokine induction of the human inducible nitric oxide synthase gene. J Biol Chem 1998; 273:15148-15156. (Pubitemid 28272813)
12. Usui M, Egashira K, Tomita H, Koyanagi M, Katoh M, Shimokawa H, et al. Important role of local angiotensin II activity mediated via type 1 receptor in the pathogenesis of cardiovascular inflammatory changes induced by chronic blockade of nitric oxide synthesis in rats. Circulation 2000; 101:305-310. (Pubitemid 30054158)
13. Zhao XS, Pan W, Bekeredjian R, Shohet RV. Endogenous endothelin-1 is required for cardiomyocyte survival in vivo. Circulation 2006; 114:830-837. (Pubitemid 44268233)
14. Hocher B, Schwarz A, Slowinski T, Bachmann S, Pfeilschifter J, Neumayer HH, et al. In-vivo interaction of nitric oxide and endothelin. J Hypertens 2004; 22:111-119. (Pubitemid 38293538)
15. Kirkby NS, Hadoke PW, Bagnall AJ, Webb DJ. The endothelin system as a therapeutic target in cardiovascular disease: great expectations or bleak house? Br J Pharmacol 2008; 153:1105-1119. (Pubitemid 351415492)
16. Quaschning T, Voss F, Relle K, Kalk P, Vignon-Zellweger N, Pfab T, et al. Lack of endothelial nitric oxide synthase promotes endothelin-induced hypertension: lessons from endothelin-1 transgenic/endothelial nitric oxide synthase knockout mice. J Am Soc Nephrol 2007; 18:730-740. (Pubitemid 46434490)
17. Quaschning T, Kocak S, Bauer C, Neumayer HH, Galle J, Hocher B. Increase in nitric oxide bioavailability improves endothelial function in endothelin-1 transgenic mice. Nephrol Dial Transplant 2003; 18: 479-483. (Pubitemid 36305650)
18. Hocher B, Ziebig R, Krause R, Asmus G, Neumayer HH, Liefeldt L, et al. Relaxin is an independent risk factor predicting death in male patients with end-stage kidney disease. Circulation 2004; 109:2266-2268. (Pubitemid 38656864)
19. Kalk P, Mach A, Thone-Reineke C,Godes M, Heiden S, Sharkovska Y, et al. Pulmonary fibrosis in L-NAME-treated mice is dependent on an activated endothelin system. Can J Physiol Pharmacol 2008; 86:541-545.
20. Aksu S, Scheler C, Focks N, Leenders F, Theuring F, Salnikow J, et al. An iterative calibration method with prediction of posttranslational modifications for the construction of a two-dimensional electrophoresis database of mouse mammary gland proteins. Proteomics 2002; 2:1452-1463. (Pubitemid 35340026)
21. Zimny-Arndt U, Schmid M, Ackermann R, Jungblut PR. Classical proteomics: two-dimensional electrophoresis/MALDI mass spectrometry. Methods Mol Biol 2009; 492:65-91.
22. Hocher B, Schwarz A, Fagan KA, Thone-Reineke C, El-Hag K, Kusserow H, et al. Pulmonary fibrosis and chronic lung inflammation in ET-1 transgenic mice. Am J Respir Cell Mol Biol 2000; 23:19-26. (Pubitemid 30597091)
23. Kalk P, Westermann D, Herzfeld S, Relle K, Pfab T, Bauer C, et al. Additional lack of iNOS attenuates diastolic dysfunction in aged ET-1 transgenic mice. Can J Physiol Pharmacol 2008; 86:353-357. (Pubitemid 351821128)
24. Han B, Hasin Y. Cardiovascular effects of natriuretic peptides and their interrelation with endothelin-1. Cardiovasc Drugs Ther 2003; 17:41-52. (Pubitemid 36898097)
25. Sun Y, CarreteroOA, Xu J, Rhaleb NE, Yang JJ, Pagano PJ, et al. Deletion of inducible nitric oxide synthase provides cardioprotection in mice with 2-kidney, 1-clip hypertension. Hypertension 2009; 53:49-56.
26. Bergamini C, Cicoira M, Rossi A, Vassanelli C. Oxidative stress and hyperuricaemia: pathophysiology, clinical relevance, and therapeutic implications in chronic heart failure. Eur J Heart Fail 2009; 11:444-452.
27. Chae HZ, Kim HJ, Kang SW, Rhee SG. Characterization of three isoforms of mammalian peroxiredoxin that reduce peroxides in the presence of thioredoxin. Diabetes Res Clin Pract 1999; 45:101-112. (Pubitemid 29457756)
28. Wagner E, Luche S, Penna L, Chevallet M, Van Dorsselaer A, Leize-Wagner E, et al. A method for detection of overoxidation of cysteines: peroxiredoxins are oxidized in vivo at the active-site cysteine during oxidative stress. Biochem J 2002; 366 (Pt 3):777-785.
29. Cullingford TE, Wait R, Clerk A, Sugden PH. Effects of oxidative stress on the cardiac myocyte proteome: modifications to peroxiredoxins and small heat shock proteins. J Mol Cell Cardiol 2006; 40:157-172. (Pubitemid 43012127)
30. Choi HJ, Kang SW, Yang CH, Rhee SG, Ryu SE. Crystal structure of a novel human peroxidase enzyme at 2.0 A resolution. Nat Struct Biol 1998; 5:400-406. (Pubitemid 28211179)
31. Manevich Y, Feinstein SI, Fisher AB. Activation of the antioxidant enzyme 1-CYS peroxiredoxin requires glutathionylation mediated by heterodimerization with pi GST. Proc Natl Acad Sci USA 2004; 101:3780-3785. (Pubitemid 38381055)
32. Hayes JD, Flanagan JU, Jowsey IR. Glutathione transferases. Annu Rev Pharmacol Toxicol 2005; 45:51-88. (Pubitemid 40261798)
33. Zhou SG, Wang P, Pi RB,Gao J, Fu JJ, Fang J, et al. Reduced expression of GSTM2 and increased oxidative stress in spontaneously hypertensive rat. Mol Cell Biochem 2008; 309:99-107.
34. Doran P, Gannon J, O'Connell K, Ohlendieck K. Aging skeletal muscle shows a drastic increase in the small heat shock proteins alphaB-crystallin/ HspB5 and cvHsp/HspB7. Eur J Cell Biol 2007; 86:629-640. (Pubitemid 47408714)
35. Kakita T, Hasegawa K, Iwai-Kanai E, Adachi S, Morimoto T, Wada H, et al. Calcineurin pathway is required for endothelin-1-mediated protection against oxidant stress-induced apoptosis in cardiac myocytes. Circ Res 2001; 88:1239-1246. (Pubitemid 32587839)
36. Bamburg JR, McGough A, Ono S. Putting a new twist on actin: ADF/ cofilins modulate actin dynamics. Trends Cell Biol 1999; 9:364-370. (Pubitemid 29447718)
37. Huang YS, Wang SM, Hsu KL, Tseng YZ, Wu JC. Mechanism of oleic acidinduced myofibril disassembly in rat cardiomyocytes. J Cell Biochem 2007; 102:638-649.
38. Kim JS, Huang TY, Bokoch GM. Reactive oxygen species regulate a slingshot-cofilin activation pathway. Mol Biol Cell 2009; 20:2650-2660.
39. Yoshida M, Minamisawa S, Shimura M, Komazaki S, Kume H, Zhang M, et al. Impaired Ca2\+ store functions in skeletal and cardiac muscle cells from sarcalumenin-deficient mice. J Biol Chem 2005; 280:3500-3506. (Pubitemid 40223815)
40. Hunter JC, Zeidan A, Javadov S, Kilic A, Rajapurohitam V, Karmazyn M. Nitric oxide inhibits endothelin-1-induced neonatal cardiomyocyte hypertrophy via a RhoA-ROCK-dependent pathway. J Mol Cell Cardiol 2009; 47:810-818.
41. Cheng TH, Shih NL, Chen CH, Lin H, Liu JC, Chao HH, et al. Role of mitogen-activated protein kinase pathway in reactive oxygen speciesmediated endothelin-1-induced beta-myosin heavy chain gene expression and cardiomyocyte hypertrophy. J Biomed Sci 2005; 12:123-133. (Pubitemid 40576770)
42. Dong HY, Zhang ZM, Zhou ZX. Effects of endothelin-1 on differentiation of cardiac myocyte induced from rabbit bone marrow stromal cells. Chin Med J (Engl) 2006; 119:832-839.
43. Muller-Brunotte R, Kahan T, Malmqvist K, Edner M. Blood pressure and left ventricular geometric pattern determine diastolic function in hypertensive myocardial hypertrophy. J Hum Hypertens 2003; 17:841-849. (Pubitemid 38028641)
44. Huang C, Zhou Q, Liang P, Hollander MS, Sheikh F, Li X, et al. Characterization and in vivo functional analysis of splice variants of cypher. J Biol Chem 2003; 278:7360-7365. (Pubitemid 36800739)
45. Arimura T, Hayashi T, Terada H, Lee SY, Zhou Q, Takahashi M, et al. A Cypher/ZASP mutation associated with dilated cardiomyopathy alters the binding affinity to protein kinase C. J Biol Chem 2004; 279:6746-6752. (Pubitemid 38248815)
46. Zheng M, Cheng H, Li X, Zhang J, Cui L, Ouyang K, et al. Cardiac-specific ablation of Cypher leads to a severe form of dilated cardiomyopathy with premature death. Hum Mol Genet 2009; 18:701-713.
47. Alvarez BV, Johnson DE, Sowah D, Soliman D, Light PE, Xia Y, et al. Carbonic anhydrase inhibition prevents and reverts cardiomyocyte hypertrophy. J Physiol 2007; 579 (Pt 1):127-145.
48. Recchia FA. Role of nitric oxide in the regulation of substrate metabolism in heart failure. Heart Fail Rev 2002; 7:141-148. (Pubitemid 34624802)
49. Sharma S, Sud N, Wiseman DA, Carter AL, Kumar S, Hou Y, et al. Altered carnitine homeostasis is associated with decreased mitochondrial function and altered nitric oxide signaling in lambs with pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 2008; 294:L46-L56. (Pubitemid 351380317)
50. Sinatra ST. Metabolic cardiology: the missing link in cardiovascular disease. Altern Ther Health Med 2009; 15:48-50.
51. Calo LA, Pagnin E, Davis PA, Semplicini A, Nicolai R, Calvani M, et al. Antioxidant effect of L-carnitine and its short chain esters: relevance for the protection from oxidative stress related cardiovascular damage. Int J Cardiol 2006; 107:54-60. (Pubitemid 41767518)
52. Stanley WC, Chandler MP. Energy metabolism in the normal and failing heart: potential for therapeutic interventions. Heart Fail Rev 2002; 7:115-130. (Pubitemid 34624800)
53. Kaye DM, Krum H. Drug discovery for heart failure: a new era or the end of the pipeline? Nat Rev Drug Discov 2007; 6:127-139. (Pubitemid 46758752)
54. Baumgartner MR, Almashanu S, Suormala T, Obie C, Cole RN, Packman S, et al. The molecular basis of human 3-methylcrotonyl-CoA carboxylase deficiency. J Clin Invest 2001; 107:495-504. (Pubitemid 32167996)
55. Foker JE, Einzig S, Wang T. Adenosine metabolism and myocardial preservation. Consequences of adenosine catabolism on myocardial highenergy compounds and tissue blood flow. J Thorac Cardiovasc Surg 1980; 80:506-516. (Pubitemid 11225896)
56. Cronstein BN, Kramer SB, Rosenstein ED, Weissmann G, Hirschhorn R. Adenosine modulates the generation of superoxide anion by stimulated human neutrophils via interaction with a specific cell surface receptor. Ann N Y Acad Sci 1985; 451:291-301. (Pubitemid 16199069)
57. Tiranti V, Viscomi C, Hildebrandt T, Di Meo I, Mineri R, Tiveron C, et al. Loss of ETHE1, a mitochondrial dioxygenase, causes fatal sulfide toxicity in ethylmalonic encephalopathy. Nat Med 2009; 15:200-205.
58. Schorlemmer A, Matter ML, Shohet RV. Cardioprotective signaling by endothelin. Trends Cardiovasc Med 2008; 18:233-239.